Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent signed by parent(s)/legal guardians of the pediatric patient in compliance with the local laws and regulations. In addition signed children's assent form according to local requirements~* Male or female in- or out-patients from neonates (full term) to \<17 years at the time of randomization~* Patient weight at least 3.2 kg~* Histologically, and/or cytologically (or imaging in the case of brain tumors) confirmed malignant disease~* Naïve or non-naïve to chemotherapy~* Scheduled and eligible to receive at least one of the moderately or highly emetogenic chemotherapeutic agents on Study Day 1~* For patients aged ≥ 10 years to \<17 years: ECOG PS ≤ 2~* For patients with known hepatic impairment: in the Investigator's opinion the impairment should not jeopardize patient's safety during the study~* For patients with known renal impairment: in the Investigator's opinion the impairment should not jeopardize patient's safety during the study~* For patients with known history or predisposition to cardiac abnormalities: in the Investigator's opinion the history/predisposition should not jeopardize patient's safety during the study~* For patients with known clinically relevant abnormal laboratory values: in the Investigator's opinion the abnormality should not jeopardize the patient's safety during the study~* Fertile patients (male or female) must use reliable contraceptive measures~* Female patients who have attained menarche must have a negative pregnancy test at the screening visit (Visit 1) and at study treatment visit (Visit 2)~Exclusion Criteria:~* Lactating or pregnant female patient~* Patient has received total body irradiation, upper abdomen radiotherapy, radiotherapy of the cranium, craniospinal regions or the pelvis within 1 week prior to study entry (screening)~* Scheduled to receive concomitant total body irradiation, radiotherapy of the upper abdomen, lower thorax region, or cranium/craniospinal regions up to 24 hours after study drug administration~* Known history of allergy to any component or other contraindications to any 5-HT3 receptor antagonists~* Active infection~* Uncontrolled medical condition~* Marked baseline prolongation of QTc interval \[QTcB or QTcF \> 460 msec\] in any of the ECG assessments at screening. For this purpose, assessment will rely on the automatic interpretation by the ECG machine~* Patient suffering from ongoing vomiting from any organic etiology (including patients with history of gastric outlet obstruction or intestinal obstruction due to adhesions or volvulus) or patients with hydrocephalus~* Patient who experienced any vomiting, retching, or nausea within 24 hours prior to the administration of the study drug~* Patient who received any drug with potential anti-emetic effect within 24 hours prior to administration of study treatment, including but not limited to:~* NK1- receptor antagonists (e.g. aprepitant)~* 5-HT3 antagonists (e.g., ondansetron, granisetron, dolasetron);~* Phenothiazines (e.g., perphenazine, prochlorperazine, promethazine, fluphenazine, chlorpromazine, thiethylperazine);~* Butyrophenones (e.g., droperidol, haloperidol);~* Benzamides (e.g., metoclopramide, alizapride);~* Corticosteroids (e.g., prednisone, methylprednisolone; except inhaled steroids for respiratory disorders and topical steroids for skin disease with doses of ≤ 10 mg of prednisone daily or its equivalent); Corticosteroids foreseen in the chemotherapy regimen or to reduce intracranial pressure are allowed. According to the guidelines1,2, patients will receive also dexamethasone as a co-medication in accordance with standard clinical practice and if deemed appropriate by the Investigator.~* Dimenhydrinate; Hydroxyzine; Domperidone; Lorazepam; Cyclizine; Cannabinoids; Scopolamine; Trimethobenzamide HCl; Meclizine hydrochloride; Pseudoephedrine HCl;~* Over the Counter (OTC) antiemetics, OTC cold or OTC allergy medications;~* Herbal preparations containing ephedra or ginger.~* Patient aged ≤ 6 years who received any investigational drug (defined as a medication with no marketing authorization granted for any age group and any indication) within 90 days prior to Day 1, or patient aged \> 6 years who received any investigational drug within 30 days prior to Day 1 or is expected to receive investigational drugs prior to study completion~* Patient who participated in any previous trial with palonosetron

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Palonosetron 10 mcg/kg (Type: EXPERIMENTAL): Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron
- Palonosetron 20 mcg/kg (Type: EXPERIMENTAL): Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron
- Ondansetron (Type: ACTIVE_COMPARATOR): Ondansetron and placebo to Palonosetron~Drug:~Comparator: Ondansetron

Based on this trial design, predict the completion outcome and termination type (if applicable).